ArticleCell death discovery2026
Leveraging drug-specific genes to identify sensitizers for resistant cancer cell lines.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic resistance remains a major obstacle in oncology, often arising from transcriptional reprogramming that enables cancer cells to escape drug-induced cytotoxicity. We aimed to develop a computational-experimental strategy to identify compounds capable of reversing resistance phenotypes. We integrated previously defined Drug-Specific Genes (DSGs), expression markers of drug sensitivity or resistance, with perturbational profiles from the Connectivity Map (CMap). Candidate compounds were prioritized based on their predicted ability to shift DSG expression toward a sensitized state. The top-ranked compound was validated in resistant HeLa and NCI-H1299 cell lines using BMS-345541 and Vorinostat as primary agents. Cell viability, apoptosis, and cell cycle progression were assessed. Chaetocin consistently emerged as a leading sensitizer in silico. Experimental validation confirmed that chaetocin enhanced the activity of BMS-345541 in HeLa cells and Vorinostat in NCI-H1299 cells. Combination treatments reduced cell viability, induced apoptosis, and promoted G2/M cell cycle arrest compared with primary drugs alone. DSG-guided transcriptional reversal offers a rational framework for overcoming therapeutic resistance. Our findings demonstrate that chaetocin can restore drug sensitivity in resistant cancer models, supporting its potential as a resistance-modulating agent in combination therapies. Given its epigenetic activity, chaetocin aligns with the emerging role of epigenetic modulators as promising partners in oncological co-treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.